Background: The object of this study was to evaluate the safety and efficacy of metronomic chemotherapy in combination with bevacizumab and erlotinib in patients with HER2-negative (HER2-) metastatic breast cancer (MBC) and poor hormone receptor expression. Patients and Methods: Patients with untreated MBC were candidates to receive metronomic oral capecitabine (500 mg thrice daily) and cyclophosphamide (50 mg daily) plus bevacizumab (15 mg/kg every 3 weeks) and erlotinib (100 mg daily). Results: Of 24 patients assessable for response, we observed 1 complete response (CR, 4%), 14 partial responses (58%), 5 patients with stable disease greater than 9 weeks' duration (SD, 21%), and 1 patient (4%) with early progression of disease. The overall clinical benefit (CB) (CR + partial response + SD > 24 weeks) was 75% (95% confidence interval [CI], 53%-90%). Median time to progression was 43 weeks (95% CI, 21-69). Patients with low levels of circulating endothelial progenitors (CEPs) at baseline had a significantly improved progression-free survival (PFS). Toxicity was generally mild. Grade 3 toxicity included diarrhea (n = 1), thrombosis (n = 1), and hypertension (n = 2). Grade 2 adverse events included diarrhea (n = 5), hand-foot syndrome (n = 13), and hypertension (n = 4). Conclusion: Treatment with metronomic chemotherapy in combination with bevacizumab and erlotinib was effective in HER2-, estrogen receptor (ER)- and progesterone receptor (PR)-poor advanced breast cancer.

Montagna, E., Cancello, G., Bagnardi, V., Pastrello, D., Dellapasqua, S., Perri, G., et al. (2012). Metronomic Chemotherapy Combined With Bevacizumab and Erlotinib in Patients With Metastatic HER2-Negative Breast Cancer: Clinical and Biological Activity. CLINICAL BREAST CANCER, 12(3), 207-214 [10.1016/j.clbc.2012.03.008].

Metronomic Chemotherapy Combined With Bevacizumab and Erlotinib in Patients With Metastatic HER2-Negative Breast Cancer: Clinical and Biological Activity

BAGNARDI, VINCENZO;
2012

Abstract

Background: The object of this study was to evaluate the safety and efficacy of metronomic chemotherapy in combination with bevacizumab and erlotinib in patients with HER2-negative (HER2-) metastatic breast cancer (MBC) and poor hormone receptor expression. Patients and Methods: Patients with untreated MBC were candidates to receive metronomic oral capecitabine (500 mg thrice daily) and cyclophosphamide (50 mg daily) plus bevacizumab (15 mg/kg every 3 weeks) and erlotinib (100 mg daily). Results: Of 24 patients assessable for response, we observed 1 complete response (CR, 4%), 14 partial responses (58%), 5 patients with stable disease greater than 9 weeks' duration (SD, 21%), and 1 patient (4%) with early progression of disease. The overall clinical benefit (CB) (CR + partial response + SD > 24 weeks) was 75% (95% confidence interval [CI], 53%-90%). Median time to progression was 43 weeks (95% CI, 21-69). Patients with low levels of circulating endothelial progenitors (CEPs) at baseline had a significantly improved progression-free survival (PFS). Toxicity was generally mild. Grade 3 toxicity included diarrhea (n = 1), thrombosis (n = 1), and hypertension (n = 2). Grade 2 adverse events included diarrhea (n = 5), hand-foot syndrome (n = 13), and hypertension (n = 4). Conclusion: Treatment with metronomic chemotherapy in combination with bevacizumab and erlotinib was effective in HER2-, estrogen receptor (ER)- and progesterone receptor (PR)-poor advanced breast cancer.
Articolo in rivista - Articolo scientifico
Bevacizumab; Erlotinib; Metronomic chemotherapy
English
2012
12
3
207
214
none
Montagna, E., Cancello, G., Bagnardi, V., Pastrello, D., Dellapasqua, S., Perri, G., et al. (2012). Metronomic Chemotherapy Combined With Bevacizumab and Erlotinib in Patients With Metastatic HER2-Negative Breast Cancer: Clinical and Biological Activity. CLINICAL BREAST CANCER, 12(3), 207-214 [10.1016/j.clbc.2012.03.008].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/30993
Citazioni
  • Scopus 57
  • ???jsp.display-item.citation.isi??? 50
Social impact